SPONSORED BY SICA MEDIA AND DISSEMINATED ON BEHALF OF CITIUS PHARMACEUTICALS, INC.*

Good Morning Market Enthusiast,

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) isn’t waiting for its FDA-approved cancer therapy LYMPHIR™ to hit shelves—it’s already arming its commercial team with AI.

This morning, Citius Oncology unveiled a proprietary machine-learning platform designed to supercharge the LYMPHIR launch—an adaptive system that pinpoints the exact prescribers treating patients who could benefit, then fine-tunes in real-time using live U.S. claims data. (13)

The market’s noticing: already up nearly 10 cents premarket on rising volume, with enthusiasm clearly circling this lean float ahead of what could be one of 2025’s biggest oncology rollouts.

For a company with just ~16M shares in the float, that’s a serious edge—turning a lean salesforce into a precision strike team right as attention builds on the tape.

Pair that with:

🤏 A float that can move on a whisper
🎯 Wall Street’s boldest price target still sitting at $6 (6)
🏛️ Recent financings and a fully FDA-approved asset ready to commercialize (2)(10)(11)(12)

…and the setup here is getting hard to ignore.

(1)

If you like being early to the story before the algorithms, headlines, and momentum chasers catch on, keep reading. Below are five concrete catalysts—not wish-list hopes—lined up:

⚡ 1. LYMPHIR™ — From FDA Stamp to Revenue Stampede 

Why it matters

LYMPHIR treats a rare skin-related lymphoma with few good options today. Management pegs the starting U.S. market at $400 million-plus. (2)

The medication enjoys a 12-year exclusivity window, meaning copycats stay on the sidelines until at least 2036. (1)(2)

Proof they’re ready

• Commercial batches boxed and labeled with a 60-month shelf life (2)
• Permanent J-code and NCCN-guideline inclusion already secured (2)
• Laser-focused 25-rep team using ML targeting to reach the small cohort of prescribers who write most CTCL scripts (1)
• Cardinal Health distribution agreement signed for nationwide reach (4)
• Cencora added as an additional wholesale distributor to expand access and redundancy at launch (9)

When to watch

First shipments are slated for the fourth quarter of 2025. (2) In rare-oncology launches, even a handful of real-world prescriptions can swing sentiment long before full-quarter revenue prints.

🔭 2. Street-Target Gravity Toward the $6 Mark

Various analysts cover CTXR, and the loftiest call is $6, ≈ +250 percent upside. (6) With so few voices in the choir and 16 million shares in the float, a single initiation or target hike can jolt the tape.

Upcoming checkpoints

• November 2025 earnings call → first public readout on LYMPHIR orders
• January 2026 → 90-day demand snapshot from specialty distributors

🩸 3. Mino-Lok® — Next in Line for FDA (decision potentially as early as mid-2026)

Hospitals dread catheter bloodstream infections; no approved medicine exists to salvage infected lines. (1)

What Mino-Lok proved

• Catheters stayed functional beyond the six-week study window vs 33 days for control (p = 0.0006) (1)
• Doubled overall treatment success with zero medication-related serious adverse events (1)
• Holds Qualified Infectious Disease Product status, triggering six-month Priority Review and five bonus years of exclusivity (1)

Timeline

Citius targets an NDA filing late 2025, putting an approval verdict mid-2026. (1)

🌐 4. Halo-Lido — First Prescription Option for a Common Pain (Phase 3 start early 2026)

More than 10 million U.S. adults wrestle with hemorrhoid symptoms each year, yet there’s no prescription cream on the market.

• Phase 2b showed meaningful symptom relief versus either ingredient alone (1)
• A patient-friendly phone app captured outcomes—an FDA-friendly way to prove benefit (1)
• Continuing engagement with the FDA will guide the next phase of development for Halo-Lido (1)

If cleared, clinicians would finally have an Rx option, and straightforward education could accelerate adoption.

🌬️ 5. Structural Tailwinds — Lean Float, Fresh Cash, Hidden Bonus

• Tiny float: 16 million shares (1)
• June financing: $6 million upfront with up to $15.8 million on full warrant exercise, earmarked for launch support (3)
• Q3 update: CTXR reported gross financings of ~$12.5 million during fiscal Q3 2025, with an additional $9.0 million raised by the oncology subsidiary in July 2025 (10)(11)(12)
• Insider commitment: Founders have contributed roughly $26 million of personal capital (1)
• Hidden kicker: CTXR still owns about 92 percent of its oncology spin-off CTOR (1)
• Nasdaq compliance restored on July 8, 2025—the delisting cloud is gone (5)

🔄 Bonus Flywheel — Combo Trials Could Extend the Story

Early academic studies pair LYMPHIR with KEYTRUDA® and next-gen CAR-T therapies, showing a 27 percent objective response rate in heavily pre-treated solid tumors. (1) Positive updates could widen LYMPHIR’s reach well beyond the initial niche.

📊 Hidden-Equity Math — Why the Spin-Off Stake Matters

Ownership: The parent still controls ≈92 percent of the subsidiary’s outstanding shares. (8)

Subsidiary market cap: recent levels around $126 million (8)

Parent market cap: recent levels around $19 million (3)

Back-of-the-envelope: that stake equates to roughly $115 million (92 percent × $126M), or > 6.5× the parent’s entire quoted valuation. The embedded value is hiding in plain sight and could re-price fast if either ticker draws fresh attention or the parent opts to unlock even a slice of its holding.

Pulling It Together — The Simple Angle

Low share count meets near-term revenue switch.

• An FDA-approved therapy inches from first sales
• A second late-stage winner aims for speed-lane review
• A consumer-friendly cream targets a huge everyday problem
• Scarce shares, insider backing, and compliance now in the clear

That imbalance is why Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) could flip from background noise to front-page material before many casual watchers know what happened. Early seats rarely stay available once the crowd realizes the show has already started.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/4kFen9k
2. https://finance.yahoo.com/quote/CTXR/key-statistics/
3. https://finance.yahoo.com/quote/CTXR/
4. https://finance.yahoo.com/news/citius-oncology-anticipates-commercial-launch-120800335.html
5. https://finance.yahoo.com/news/citius-pharmaceuticals-announces-closing-registered-123500996.html
6. https://finance.yahoo.com/news/citius-oncology-enters-distribution-services-123700606.html
7. https://www.tipranks.com/stocks/ctxr/forecast#
8. https://finance.yahoo.com/quote/CTOR/
9. https://finance.yahoo.com/news/citius-oncology-expands-distribution-network-123200988.html 
10. https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-203000029.html
11. https://finance.yahoo.com/news/citius-oncology-announces-closing-9-203000291.html
12. https://finance.yahoo.com/news/citius-oncology-announces-pricing-9-131500533.html 

13. https://bit.ly/47atCnM

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 08/21/2025 and ending on 08/22/2025 (the “Campaign”) to publicly disseminate information about Citius Pharmaceuticals, Inc. (CTXR:US). Momentum Media LLC has been compensated $10,000 and are owed an additional $0 for the Campaign. To date we have been paid $30,000. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.